http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106479973-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106479973-B |
| titleOfInvention | A kind of external IAK immunocyte cultural method |
| abstract | The invention belongs to tumor preventions and treatment technology field, and in particular to a kind of external IAK immunocyte cultural method of optimization.This method comprises: extracting peripheral blood mononuclear cells, A, B, C, D reagent of special designing is then added step by step, in batches with incubation time difference, and cultivates to specific time.The present invention is by optimizing IAK immunocyte culture system in vitro, so that the technology is consistent or has preferable improvement in terms of the indexs such as cell amplification ability, effector cell's phenotype and ratio, killing ability, especially effector cell's ratio, the killing ability of effector cell, which have, is obviously improved, so that the technology can preferably be used for oncotherapy, thus there is preferable practical value and promote and apply meaning. |
| priorityDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.